All In Biotech

Drug Trial Radar · NCT01211847

Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind DCCR-Fenofibrate Combination Extension

Last checked: Nov 19, 2026Latest source record: Jan 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Oct 2010

Primary completion

Sep 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Essentialis, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Sep 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Once a day oral administration with DCCR helps lower triglycerides

Conditions

  • Hypertriglyceridemia
  • Dyslipidemia

Interventions

  • Diazoxide Choline Controlled-Release TabletDrug

    DCCR 290 mg once a day for 126 days

  • PlaceboDrug

    Placebo matching DCCR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Triglyceride-lowering efficacy of DCCRTime frame: 84 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.